Venker Eric's most recent trade in Roivant Sciences Ltd was a trade of 198,413 Common Shares done . Disclosure was reported to the exchange on July 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jul 2025 | 198,413 | 1,660,636 | - | 0 | Common Shares | |
| Immunovant Inc | Eric Venker | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2025 | 1,475,000 | 1,475,000 | - | - | Capped Value Appreciation Rights | |
| Immunovant Inc | Eric Venker | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2025 | 1,300,000 | 1,300,000 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Eric Venker | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2025 | 189,900 | 189,900 | - | - | Stock Option (right to buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jul 2025 | 100,000 | 8,138,897 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Sale of securities on an exchange or to another person at price $ 11.52 per share. | 21 Jul 2025 | 100,000 | 1,462,223 | - | 11.5 | 1,152,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & Immunovant CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 21 Jul 2025 | 100,000 | 1,562,223 | - | 3.9 | 385,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 100,000 | 8,238,897 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 20 Jun 2025 | 100,000 | 1,562,223 | - | 3.9 | 385,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 11.45 per share. | 20 Jun 2025 | 100,000 | 1,462,223 | - | 11.5 | 1,145,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2025 | 785,026 | 8,338,897 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 02 Jun 2025 | 785,026 | 2,028,501 | - | 3.8 | 3,022,350 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2025 | 600,000 | 9,123,923 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 02 Jun 2025 | 600,000 | 1,677,197 | - | 3.9 | 2,310,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 11.22 per share. | 02 Jun 2025 | 566,278 | 1,462,223 | - | 11.2 | 6,353,639 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 11.07 per share. | 02 Jun 2025 | 433,722 | 1,243,475 | - | 11.1 | 4,801,303 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2025 | 100,000 | 9,723,923 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 10.95 per share. | 20 May 2025 | 100,000 | 1,077,197 | - | 11.0 | 1,095,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 20 May 2025 | 100,000 | 1,177,197 | - | 3.9 | 385,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.04 per share. | 20 May 2025 | 39,148 | 1,077,197 | - | 11.0 | 432,194 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 10.22 per share. | 20 Apr 2025 | 100,000 | 1,116,345 | - | 10.2 | 1,022,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Apr 2025 | 100,000 | 9,823,923 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 20 Apr 2025 | 100,000 | 1,216,345 | - | 3.9 | 385,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.15 per share. | 20 Apr 2025 | 10,945 | 1,116,345 | - | 10.2 | 111,092 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2025 | 602,311 | 9,923,923 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 20 Mar 2025 | 602,311 | 1,561,768 | - | 3.8 | 2,318,897 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 10.82 per share. | 20 Mar 2025 | 434,478 | 1,127,290 | - | 10.8 | 4,701,052 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2025 | 400,000 | 10,526,234 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 20 Mar 2025 | 400,000 | 1,274,979 | - | 3.9 | 1,540,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 11.06 per share. | 20 Mar 2025 | 315,522 | 959,457 | - | 11.1 | 3,489,673 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.97 per share. | 20 Mar 2025 | 10,945 | 874,979 | - | 11.0 | 120,067 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 20 Feb 2025 | 100,000 | 996,869 | - | 3.9 | 385,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2025 | 100,000 | 10,926,234 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 10.65 per share. | 20 Feb 2025 | 100,000 | 896,869 | - | 10.7 | 1,065,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.72 per share. | 20 Feb 2025 | 10,945 | 885,924 | - | 10.7 | 117,330 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 300,000 | 11,026,234 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 300,000 | 11,326,234 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 12 Feb 2025 | 300,000 | 1,032,294 | - | 3.9 | 1,155,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 12 Feb 2025 | 300,000 | 1,114,910 | - | 3.9 | 1,155,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 10.42 per share. | 12 Feb 2025 | 218,041 | 896,869 | - | 10.4 | 2,271,987 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 10.53 per share. | 12 Feb 2025 | 217,384 | 732,294 | - | 10.5 | 2,289,054 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 20 Jan 2025 | 100,000 | 832,294 | - | 3.9 | 385,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 11.28 per share. | 20 Jan 2025 | 100,000 | 732,294 | - | 11.3 | 1,128,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 100,000 | 11,626,234 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.15 per share. | 20 Jan 2025 | 8,682 | 732,294 | - | 11.1 | 96,804 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 27 Dec 2024 | 250,000 | 918,680 | - | 3.9 | 962,500 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 250,000 | 11,976,234 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 27 Dec 2024 | 250,000 | 845,580 | - | 3.9 | 962,500 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 250,000 | 11,726,234 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 11.54 per share. | 27 Dec 2024 | 177,704 | 740,976 | - | 11.5 | 2,050,704 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 11.82 per share. | 27 Dec 2024 | 176,900 | 668,680 | - | 11.8 | 2,090,958 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2024 | 100,000 | 12,226,234 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 11.49 per share. | 20 Dec 2024 | 100,000 | 595,580 | - | 11.5 | 1,149,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 20 Dec 2024 | 100,000 | 695,580 | - | 3.9 | 385,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.57 per share. | 20 Dec 2024 | 10,945 | 595,580 | - | 11.6 | 126,634 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 20 Nov 2024 | 100,000 | 706,525 | - | 3.9 | 385,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 11.32 per share. | 20 Nov 2024 | 100,000 | 606,525 | - | 11.3 | 1,132,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2024 | 100,000 | 12,326,234 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.49 per share. | 20 Nov 2024 | 10,945 | 606,525 | - | 11.5 | 125,758 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Sale of securities on an exchange or to another person at price $ 11.65 per share. | 20 Oct 2024 | 100,000 | 617,470 | - | 11.7 | 1,165,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Oct 2024 | 100,000 | 12,426,234 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 20 Oct 2024 | 100,000 | 717,470 | - | 3.9 | 385,000 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.92 per share. | 20 Oct 2024 | 10,945 | 617,470 | - | 11.9 | 130,464 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.97 per share. | 20 Sep 2024 | 10,945 | 628,415 | - | 12.0 | 131,012 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.48 per share. | 20 Aug 2024 | 10,947 | 639,360 | - | 11.5 | 125,672 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2024 | 409,000 | 409,000 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2024 | 204,000 | 650,307 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Eric Venker | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.00 per share. | 20 Jul 2024 | 10,945 | 446,307 | - | 11 | 120,395 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.80 per share. | 20 Jun 2024 | 10,945 | 457,252 | - | 10.8 | 118,206 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.37 per share. | 20 May 2024 | 16,003 | 468,197 | - | 11.4 | 181,954 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.46 per share. | 20 Apr 2024 | 16,002 | 484,200 | - | 10.5 | 167,381 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.01 per share. | 20 Mar 2024 | 16,003 | 500,202 | - | 10.0 | 160,190 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.54 per share. | 20 Feb 2024 | 16,002 | 516,205 | - | 11.5 | 184,663 | Common Shares |
| Roivant Sciences Ltd | Venker Eric | President & COO | Sale of securities on an exchange or to another person at price $ 10.92 per share. | 09 Feb 2024 | 96,950 | 532,207 | - | 10.9 | 1,058,694 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 09 Feb 2024 | 96,950 | 629,157 | - | 3.9 | 373,258 | Common Shares |
| Roivant Sciences Ltd | Venker Eric | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 96,950 | 12,526,234 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Venker Eric | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.35 per share. | 20 Jan 2024 | 12,377 | 532,207 | - | 10.4 | 128,102 | Common Shares |
| Roivant Sciences Ltd | Venker Eric | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.96 per share. | 20 Dec 2023 | 16,003 | 544,584 | - | 10.0 | 159,390 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | President & COO | Other type of transaction at price $ 10.83 per share. | 22 Aug 2023 | 16,105 | 611,813 | - | 10.8 | 174,417 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 11.89 per share. | 14 Aug 2023 | 59,811 | 627,918 | - | 11.9 | 711,153 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2023 | 59,811 | 14,523,578 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 14 Aug 2023 | 59,811 | 687,729 | - | 3.8 | 230,272 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 11.93 per share. | 03 Aug 2023 | 44,629 | 627,918 | - | 11.9 | 532,424 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 44,629 | 14,583,389 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 03 Aug 2023 | 44,629 | 672,547 | - | 3.9 | 171,822 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 11.91 per share. | 31 Jul 2023 | 117,372 | 627,918 | - | 11.9 | 1,397,901 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2023 | 117,372 | 14,705,812 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 31 Jul 2023 | 117,372 | 745,290 | - | 3.8 | 451,882 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2023 | 61,397 | 14,644,415 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 11.92 per share. | 31 Jul 2023 | 61,397 | 627,918 | - | 11.9 | 731,852 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 31 Jul 2023 | 61,397 | 689,315 | - | 3.8 | 236,378 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2023 | 16,397 | 14,628,018 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 11.86 per share. | 31 Jul 2023 | 16,397 | 627,918 | - | 11.9 | 194,468 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 31 Jul 2023 | 16,397 | 644,315 | - | 3.8 | 63,128 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 10.91 per share. | 25 Jul 2023 | 73,568 | 627,918 | - | 10.9 | 802,627 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 25 Jul 2023 | 73,568 | 701,486 | - | 3.9 | 283,237 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2023 | 73,568 | 14,846,806 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 25 Jul 2023 | 28,344 | 656,262 | - | 3.8 | 109,124 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 10.86 per share. | 25 Jul 2023 | 28,344 | 627,918 | - | 10.9 | 307,816 | Common Shares |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2023 | 28,344 | 14,920,374 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Eric Venker | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 25 Jul 2023 | 23,622 | 651,540 | - | 3.9 | 90,945 | Common Shares |